Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Summary

This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST. This study is designed to determine the Phase II dose of AMN107 and imatinib when administered together in patients with imatinib-resistant GIST, and to characterize the safety, tolerability and pharmacokinetic (PK) profile of this combination.

Timeline

Start

2005-08

Primary completion

2006-11

Completion

2006-11

Drugs

Indications